Stocks · Coverage Archive

$REPL

10.56 ▲ 95.19%

Every Regards of Wallstreet article on $REPL, newest first — 1 story and counting.

  1. 2026-07-31 · 7 min read

    Why Is Replimune (REPL) Stock Up 127%? An FDA Panel Backed RP1 After Two Rejections, and the Decision Lands This Weekend

    Replimune surged 127% after an FDA panel voted 10-3 that RP1 works in advanced melanoma, six days after the stock crashed 32%. The PDUFA date is August 2. Why this is not over.

New to options? See our plain-English strategy playbook →

The Sunday Setup

Enjoyed this breakdown? Don’t miss the next market setup.

Get deep-dive analyses delivered to your inbox every Sunday. Free, and built for retail investors.